Latest Options News

Wingara AG Limited’s planned funding placement with Terra Firma Equity Limited has fallen through, prompting legal considerations and a pause on a key board appointment.

Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.

Epsilon Healthcare has launched a $1 million loan note issue aimed at supporting its working capital and diversification efforts, with a 10% interest rate and potential share conversion.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

AKORA Resources has appointed Peter Bird as its new Managing Director and CEO, marking a strategic leadership change aimed at advancing the Bekisopa Iron Ore Project and securing critical funding and partnerships.

Taruga Minerals has reported its highest silver assay to date from the Thowagee Project in Western Australia, alongside significant lead and zinc results that extend the known mineralised strike by 200 metres northeast.

NRW Holdings faces a significant threat to its $113.3 million secured debt after the South Australian Government proposed legislation that could invalidate key lease agreements underpinning its security interests in Whyalla Ports.

Celsius Resources Limited has launched an offer of up to 423.95 million new options to key placement participants, including Silvercorp Metals and its lead manager, aiming to support ongoing project funding without immediate capital inflow.

QBE Insurance Group has priced a AUD 600 million subordinated notes issuance, strengthening its capital base under APRA regulations with notes maturing in 2036.

Xero Limited reported a robust FY25 with 23% revenue growth to NZ$2.1 billion and a 30% rise in net profit, driven by strategic investments in AI and product innovation. Leadership changes and a CEO pay review underscore the company’s global ambitions.

Future Metals NL has announced a partially underwritten entitlement offer aiming to raise approximately AUD 2.64 million to support development of its Eileen Bore Project and working capital needs. The offer opens to eligible shareholders on 15 May 2025 and closes on 30 May 2025.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.